About Delcath
Delcath is a company based in New York (United States) founded in 1987. It operates as a HealthTech. The company has 96 employees as of December 31, 2024. Delcath offers products and services including HEPZATO KIT™ and CHEMOSAT®. Delcath operates in a competitive market with competitors including TriSalus Life Sciences, Cooler Heads, Luminate Medical, Embolx and Cognos Therapeutics, among others.
- Headquarter New York, United States
- Employees 96 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Delcath Systems, Inc.
-
Annual Revenue
$37.2 M (USD)1701.69as on Dec 31, 2024
-
Net Profit
-$26.39 M (USD)44.66as on Dec 31, 2024
-
EBITDA
-$12.18 M (USD)67.99as on Dec 31, 2024
-
Latest Funding Round
$16.3 M (USD), Post-IPO
Dec 30, 2024
-
Investors
Canaccord Genuity Group
& 8 more
-
Employee Count
96
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Delcath
Delcath is a publicly listed company on the NASDAQ with ticker symbol DCTH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Delcath
Delcath offers a comprehensive portfolio of products and services, including HEPZATO KIT™ and CHEMOSAT®.
Treatment for metastatic Uveal Melanoma in adults provided.
Hepatic delivery system for Melphalan perfusion offered.
People of Delcath
Unlock access to complete
Unlock access to complete
Funding Insights of Delcath
Investors in Delcath
Delcath has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Canaccord Genuity Group, Jefferies and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked |
Investor details for Delcath
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Delcath
Investment portfolio details for Delcath
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Delcath
Detailed financials for Delcath
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Delcath Comparisons
Peer comparison for Delcath
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Delcath
Delcath operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TriSalus Life Sciences, Cooler Heads, Luminate Medical, Embolx and Cognos Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drug delivery devices to treat cancers
|
|
| Locked | Locked | Locked |
Developer of cold cap system to prevent chemotherapy side effects
|
|
| Locked | Locked | Locked |
Developer of a medical device to prevent hair loss during chemotherapy
|
|
| Locked | Locked | Locked |
Catheter-based system for localized cancer therapy is being developed.
|
|
| Locked | Locked | Locked |
Cognos Therapeutics is focused on innovative neurological and oncological treatments.
|
Detailed competitors of Delcath
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Delcath
Complete news archive for Delcath
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Delcath
Delcath was founded in 1987 and raised its 1st funding round 15 years after it was founded.
Delcath is headquartered in New York, United States. It is registered at New York, New York, United States.
As of Dec 31, 2024, the latest employee count at Delcath is 96.
Annual revenue of Delcath is $37.2M as on Dec 31, 2024.
Delcath Systems, Inc. is recognized as an interventional oncology company dedicated to the treatment of primary and metastatic liver cancers. Solutions are developed to provide targeted, safe, and effective minimally-invasive treatments for patients. The impact of liver cancer, affecting 1.2 million people globally each year, is addressed through innovative products like HEPZATO KIT for metastatic Uveal Melanoma in the United States and CHEMOSAT Hepatic Delivery System in Europe. Commitment is shown in revolutionizing care for liver cancer patients by exploring beyond conventional treatment options.
Delcath's top competitors include TriSalus Life Sciences, Cooler Heads and Cognos Therapeutics.
Delcath offers HEPZATO KIT™ and CHEMOSAT®.
Yes, Delcath is publicly traded on NASDAQ under the ticker symbol DCTH.
Delcath has 9 investors. Key investors include Canaccord Genuity Group, Jefferies, Vivo Capital, Logos Capital, and BVF Partners.
The ticker symbol of Delcath is DCTH on NASDAQ.